Neuromyelitis optica or neuromyelitis optica spectrum disorders (NMOSD) are autoimmune diseases associated with a disease-specific autoantibody directed against the water channel protein aquaporin-4. While almost all patients with NMOSD show a relapsing-remitting course, just 2% of patients present with a progressive course, suggesting that preventing acute attacks can lead to stable remission and avoid progression of the condition. Standard immunotherapy, immunosuppressive agents, and corticosteroids can prevent acute attacks and maintain remission in the majority of patients with NMOSD. However, there is a strong need for alternative options for patients who are refractory to standard treatments. Emerging therapies targeting specific molecules related to the pathogenicity of NMOSD are currently being developed. In addition to standard intravenous high-dose corticosteroid and plasma exchange/plasmapheresis, therapies targeted at inhibiting granulocytes, complement, and vascular endothelial growth factor are anticipated for acute attacks. With regard to preventive treatment of NMOSD, randomized clinical trials using monoclonal immunoglobulin G antibody targeting CD19 and CD20 on B cells, interleukin-6, and complement protein C5 are underway. There are many preclinical therapeutic agents that target aquaporin-4 and the pathogenic anti-aquaporin-4 antibody itself: complement inhibitor and T helper 17 cells based on the specific NMOSD pathology. The future goal of immunotherapies for NMOSD would be to select suitable therapies for the patient's pathological condition among off-target and molecular-target agents.
Introduction
Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) are autoimmune diseases of the central nervous system (CNS), preferentially affecting the spinal cord, optic nerve, dorsal medulla, thalamus, corpus callosum and periependymal brain lesions. NMOSD used to be considered as a variant of multiple sclerosis (MS), which is a representative demyelinating disease of the CNS. However, when the disease specific autoantibody, NMOimmunoglobulin G (IgG), was discovered, 1 and found to target water channel protein aquaporin-4 (AQP4), 2 the pathogenesis of NMOSD could be elucidated. [3] [4] [5] [6] AQP4 is abundantly located in the foot processes of astrocytes in the vicinity of the blood-brain barrier (BBB). Serum anti-AQP4 antibody (AQP4-Ab) levels correlate with clinical disease activity, 7 indicating the following pathogenicity in NMOSD: 8 
(i) disruption
and hyperpermeability of the BBB; 9 (ii) astrocytic damage with loss of AQP4; 10, 11 (iii) activation of neutrophils, eosinophils and complement; 12 and (iv) neuronal cell and oligodendrocyte death by glutamate excitotoxicity. 13, 14 The advances in understanding the pathological mechanisms of NMOSD yielded a new strategy for the prevention and management of acute exacerbations. In consideration of the specific pathogenesis associated with AQP4-Ab, the diagnostic criteria were provided in 2006, 15 and further revised in 2015. 16 In general, the treatment for acute attacks in NMOSD is similar to MS treatment. High-dose corticosteroids, in particular intravenous methylprednisolone (IVMP), have been a first-line therapy.
When IVMP is ineffective, plasma exchange (PLEX) or plasmapheresis (immunoadsorption plasmapheresis [IAPP] , double filtration plasmapheresis [DFPP] ) is chosen as an escalation therapy. Compared with MS, more severe and faster inflammation is observed in the acute NMOSD phase. The inflammatory responses involve autoantibody, complement and granulocyte activation, followed by not only demyelination, but also astrocytic and neuronal damage. It should be noted that the prompt decision to shift to PLEX/IAPP/DFPP is important when patients are refractory to IVMP.
To prevent relapses and acute exacerbations of NMOSD, oral immunosuppressant drugs and corticosteroids are widely used as a first-line therapy. The immunosuppressants azathioprine, mycophenolate mofetil, methotrexate and rituximab (RTX) are typically recommended. [17] [18] [19] First-line therapies can reduce the relapse rate, but often fail to prevent attacks. Patients for whom initial treatment fails are recommended to alternate among first-line therapies or to receive second-line therapy. 20 The oral corticosteroid, prednisolone, is chosen as a combination therapy with immunosuppressants or a regimen of tapering therapy after high-dose corticosteroids after acute attacks. In Japan, oral corticosteroid monotherapy is preferentially used as an initial preventive treatment because of its faster onset compared with immunosuppressants. [21] [22] [23] In cases of its inefficiency in preventing acute attacks or when severe adverse effects occur, immunosuppressants such as azathioprine, methotrexate, tacrolimus or cyclosporine A are recommended as add-on or second-line therapy.
The aforementioned treatment algorithm contributed to the well-controlled disease activity in patients with NMOSD. However, alternative therapeutic approaches for patients who are resistant to standard immunotherapies are still required. The development of emerging therapies, including molecular-targeted drugs, has been supported by the elucidation of NMOSD pathogenesis. Therapeutic agents that target B cells, plasmablasts (PB), neutrophils, eosinophils, the classical complement pathway and AQP4-Ab itself are currently under development ( Fig. 1 ; Table 1 ).
Emerging therapies for acute exacerbations

Anti-granulocyte therapies
Neutrophil elastase inhibitor Antibody-dependent astrocyte damage, and activation and accumulation of granulocytes, including neutrophils and eosinophils, play central roles in the pathogenesis of NMOSD lesions. Several anti-granulocyte agents are currently under development for acute attacks in NMOSD.
Sivelestat is a neutrophil elastase inhibitor involved in neutrophil migration and phagocytosis. It is approved in Japan for treating acute respiratory distress syndrome, which is associated with systemic Figure 1 Targets in emerging therapies in neuromyelitis optica spectrum disorder pathology. The therapeutic targets and emerging therapies in the periphery and central nervous system are shown (red arrows and red letters). AQP4, aquaporin-4; AQP4-Ab, aquaporin-4 antibody; BAFF, B-cell activating factor; BBB blood-brain barrier; IL, interleukin; IVIg, intravenous immunoglobulin; Th17, T helper 17; VEGF, vascular endothelial growth factor. inflammatory response syndrome. Neutrophil elastase is elevated in the patients' sera, and inhibition of neutrophil elastase reduced antibody-dependent cytotoxicity in a mouse model of experimental autoimmune encephalomyelitis. 24, 25 This finding suggests sivelestat as a potential treatment for acute attacks in NMOSD. Although phase I and II clinical trials to confirm the efficacy of sivelestat for acute NMOSD attacks were discontinued for various reasons, it is still considered as a promising therapeutic option from the standpoint of granulocyte-targeted therapy.
Alpha 1-antitrypsin (AAT) is a major protease inhibitor that protects lung tissues from proteolytic damage by inhibiting neutrophil elastase. Accordingly, AAT is a therapeutic agent for early-onset pulmonary emphysema in patients with AAT deficiency. 26 In addition, AAT modulates inflammatory responses, such as the reduction of pro-inflammatory cytokines, and blockade of leukocyte degranulation and migration. 27 Furthermore, AAT has a potential therapeutic value in autoimmune diseases, and a phase I clinical trial for NMOSD is currently underway.
Antihistamine
In the presence of complement, eosinophils increased complement-dependent cell-mediated cytotoxicity in mouse models of NMOSD. Cetirizine, a second-generation antihistamine, has an eosinophil-stabilizing mechanism of action, and is approved in Japan for allergic rhinitis and urticaria. Cetirizine could reduce antibody/eosinophil-dependent cytotoxicity and diminish NMO lesions. 28 Therefore, cetirizine is expected to be a future option for acute NMO treatment.
Complement inhibitor
Pathological impairment in NMOSD is partly mediated by activation of the classical complement pathway. Complement C1-esterase inhibitor (Cinryze), an inhibitor of the classical complement cascade, is approved for use in patients with hereditary angioedema. In a completed phase Ib clinical trial for NMOSD, 10 patients received 2000 units daily of C1-esterase inhibitor infusions for 3 days as an addon therapy in combination with 5-day IVMP. 29 The dose of C1-esterase inhibitor was chosen based on clinical data in myocardial infarction and sepsis. 30, 31 No serious adverse events, including thromboembolism, were reported. Furthermore, nine patients recovered to their pre-attack neurological conditions, although two required plasmapheresis as an escalation therapy. In a rat model of NMOSD, C1-esterase inhibitor partially inhibited AQP4-Ab-dependent complement-dependent cytotoxicity (CDC) in vitro, but did not inhibit serum complement activity or reduce inflammatory lesions. 32 These findings show that further investigation is required to explore the mechanism of action of C1-esterase inhibitor.
Vascular endothelial growth factor inhibitor
AQP4-Ab plays an important role in BBB breakdown after an acute NMOSD attack. Vascular endothelial growth factor (VEGF) exacerbates the disruption of the BBB in mice with an inflammatory disease involving the CNS. Humanized anti-VEGF monoclonal immunoglobulin (Ig) G1 antibody, bevacizumab, binds to VEGF and inhibits its interaction with VEGF receptors (VEGFR-1, VEGFR-2) on the surface of endothelial cells. Bevacizumab is approved for treating malignancy, such as colon cancer, nonsmall-cell cancer, breast cancer and glioblastoma. With regard to NMOSD, a phase Ib clinical study using anti-VEGF monoclonal antibody bevacizumab has been completed. 33 A total of 10 patients with acute attacks received a single infusion of 10 mg/kg bevacizumab on day 1, in addition to a 5-day course of IVMP (1000 mg/day). Three patients recovered to pre-attack neurological function without additional escalation therapy.
Intravenous immunoglobulin
Intravenous immunoglobulin (IVIg) plays a pivotal role in immunomodulation including neutralizing autoantibodies, regulating the complement system, and blocking inflammatory cytokines, pathogenic T cells and Fc-gamma receptors in autoimmune diseases. 34 Furthermore, IVIg is widely approved for humorally-and autoimmune-mediated neurological disorders, such as myasthenia gravis, Guillain-Barr e syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and polymyositis. Although a number of case series have shown that IVIg is effective in patients with NMOSD, phase II randomized controlled trials (NCT01845584) failed to show efficacy. 35 Nevertheless, IVIg is still considered an attractive treatment in patients who are pregnant or refractory to standard therapies.
Emerging therapies for prevention: Biologics under clinical trials
B-cell depletion therapies
Rituximab: Anti-CD20 monoclonal antibody RTX is a chimeric murine-human anti-CD20 monoclonal IgG1 antibody directed against CD20, a surface molecule on B and precursor B cells. Therefore, RTX potentially induces a directed CDC and antibody-dependent cell-mediated cytotoxicity against CD20-expressing B cells, leading to B-cell apoptosis. RTX is approved for the treatment of malignancies, such as non-Hodgkin's lymphoma, and autoimmune diseases, such as microscopic polyangiitis and Wegener's granulomatosis. The efficacy of RTX in other autoimmune diseases including relapsing-remitting MS has also been reported. [36] [37] [38] [39] The first pivotal pilot study involving RTX was reported in 2005. 40 Six of eight patients were relapse-free, and the relapse number was reduced from 2.6 per year to 0 during the treatment period. Long-term efficacy showed that 18 of 30 patients were relapse-free, and the annualized relapse rates of 26 patients markedly declined from 2.4 to 0.3. A number of open-label and retrospective studies showed the efficacy of RTX in preventing attacks of NMOSD. [41] [42] [43] A long-term follow-up study reported that 18 of 30 patients were relapse-free during RTX treatment, whereas 26 patients showed a marked annualized relapse rates reduction from 2.4 in pretreatment to 0.3 after treatment. 44 However, treatment regimens remain to be confirmed; either weekly 375 mg/m 2 RTX infusion for 4 weeks or 1000 mg infusion twice at 2-week intervals are standard regimens for induction therapy. In contrast, maintenance therapy was typically administered at regular 6-month intervals, or when the cell number of CD19 + or CD20 + B cells exceeded 0.1%, or when CD27 + memory B cells exceeded 0.05%.
Despite its effectiveness in preventing NMOSD, previous studies have reported RTX-refractory cases. 45, 46 Several speculative causes have been proposed. First, RTX can deplete only peripheral B cells, but not B cells in the CNS, suggesting that immunopathogenesis in the CNS can lead to refractoriness. Second, B-cell depletion can induce temporary elevation of the B-cell activating factor, resulting in a reactivation of AQP4-Ab. 47 Third, RTX cannot suppress AQP4-Ab production, because PB do not express CD20. Fourth, the gene polymorphism, FccRIIIA (FCGR3A), is an independent predictor of B cell depletion and clinical efficacy of RTX. 46 Leukocytopenia, exacerbation of hepatitis B, interstitial pneumonia and progressive multifocal leukoencephalopathy have been reported as serious adverse events. Infusion reaction has also occurred at a higher frequency compared with that by humanized monoclonal antibodies. Although RTX is widely used worldwide for the prevention of NMOSD attacks, it has not been approved for NMOSD in Japan, where a phase III double-blind clinical trial is currently in progress (UMIN000013453: RIN-1 and 2).
Ublituximab and ocrelizumab: Anti-CD20 monoclonal antibodies Two other monoclonal IgG1 antibodies directed against a unique CD20 epitope, ublituximab and ocrelizumab, have been newly engineered. Ocrelizumab showed lower rates of clinical progression and disease activity in both patients with relapsing-remitting MS (ocrelizumab vs interferon beta-1a) and primary progressive MS (ocrelizumab vs placebo) in randomized controlled studies. 48, 49 In contrast, clinical trials using ublituximab for relapsing-remitting MS (phase II) and NMOSD (phase I) are underway.
MEDI-551: Anti-CD19 monoclonal antibody MEDI-551 is a humanized anti-CD19 monoclonal IgG1 antibody. CD19, which is widely expressed on the B-cell lineage including AQP4-Ab producing PB, is targeted by MEDI-551. Thus, MEDI-551 mediates the antibody-dependent and cell-mediated toxicity of B cells, which results in B-cell depletion and suppression of disease activity.
Bortezomib: Proteasome inhibitor
Proteasome inhibition suppresses anti-apoptotic nuclear factor kappa B activation. The proteasome inhibitor, bortezomib, is approved for multiple myeloma, as it depletes transformed plasma cells. Bortezomib also depleted plasma cells in patients with systemic lupus erythematosus, resulting in a significant decline of the disease activity. 50 In NMOSD pathology, bortezomib can suppress the astrocytic inflammatory response by inhibiting the nuclear factor kappa B signaling pathway. 51 Little information is available about the clinical efficacy in NMOSD; however, a phase II clinical trial using bortezomib has been registered (NCT02893111).
Interleukin-6 blockade therapy: Anti-interleukin-6 receptor monoclonal antibody PB, which are a subpopulation of B cells, are capable of producing autoantibodies including AQP4-Ab. 52 The survival of PB and the production of AQP4-Ab are both promoted by interleukin-6 (IL-6), but not B-cell activating factor and a proliferation-inducing ligand. Furthermore, increased levels of IL-6 in the serum and cerebrospinal fluid of patients with NMOSD have been reported. [53] [54] [55] IL-6 exerts pleiotropic effects on immune cells, bone marrow cells and hepatocytes. In the event of infection or tissue injury, IL-6 is promptly synthesized, induces acutephase proteins, such as C-reactive protein, thus contributing to host defense and inflammatory immune responses. 56 In contrast, IL-6 dysregulation is involved in the development of autoimmune diseases. Therefore, IL-6 signal blockade therapy is a promising option to decrease disease activity in NMOSD. A humanized anti-IL-6 receptor monoclonal IgG1 antibody, tocilizumab (TCZ), has been approved for use in the treatment of rheumatoid arthritis, juvenile arthritis and Castleman's disease. We carried out a pilot study using TCZ for refractory NMOSD. 57, 58 Seven patients who received 0.8 mg/ kg i.v. TCZ monthly for 12 months showed a reduced relapse rate (from 2.9 AE 1.1 to 0.4 AE 0.8, P < 0.005) and improvement of expanded disability status scale (EDSS; from 5.1 AE 1.7 to 4.1 AE 1.6, P < 0.01). Interestingly, chronic neuropathic pain and general fatigue were gradually reduced after the initiation of TCZ administration. The immunological analysis found that AQP4-Ab was reduced after TCZ therapy, accompanied by clinical improvement. A German group also showed that TCZ is highly effective for refractory NMOSD. 59, 60 Eight patients who were refractory to rituximab had markedly reduced annualized relapse rates, from 4.0 before treatment to 0.4 after treatment, and improved EDSS, from 7.3 to 5.5. They also reported a reduction in chronic pain after TCZ therapy. More severe and intractable pain is a characteristic clinical symptom of NMOSD as compared with MS. [61] [62] [63] Neuropathic pain is associated with inflammatory cytokines IL-6, IL-1b and tumor necrosis factor-a produced by activated microglial cells, 64 suggesting that microglia and inflammatory cytokines are targets for treating neuropathic pain. 65 In a rodent model, blockade of inflammatory cytokine IL-6 mitigated neuropathic pain, including allodynia. 66 Pain relief after TCZ treatment implies that IL-6 could be associated with the pathogenicity of chronic pain in NMOSD.
Infections, leukocytopenia, anemia and hypercholesterolemia are the most common adverse effects of TCZ in patients with NMOSD. 58 Severe infectious cases have not been reported in pilot studies and case reports on NMOSD, whereas serious pneumonia and bowel perforation have been reported in patients with rheumatoid arthritis. There is concern that IL-6 signal blockade therapy might underestimate severe infection by mitigated-appearing symptoms, including low-grade fever or afebrile pneumonia and painless acute enterocolitis. Furthermore, TCZ can cause a downregulation of infectious biomarkers, such as elevation of white blood cell count, C-reactive protein and erythrocyte sedimentation rate. Patients with long-lasting infectious symptoms should be carefully monitored by X-ray and computed tomography to prevent severe infections.
Based on the results of these pilot studies, a randomized controlled trial using the next-generation anti-IL-6 receptor monoclonal antibody, SA237, is currently underway as a phase III clinical study (NCT02028884, NCT02073279).
Anti-complement therapy: Anti-C5 monoclonal antibody
Complement activation and accumulation in NMO lesions have been shown to be involved in the pathogenesis of NMOSD. 67, 68 Eculizumab (ECU) is a humanized anti-C5 monoclonal IgG2/4 antibody that inhibits the terminal complement cascade. Hemolysis and thrombogenesis are attributed to the activation of the classical complement pathway, suggesting that inhibition of the pathway can regulate hemolytic diseases. ECU has been approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome. Furthermore, the complement activation pathway is also associated with the immune system. Activation of the complement pathway induces cleavage of C5 protein into C5a and C5b, which initiates the assembly of the cytolytic terminal C5b-9 membrane attack complex. Both C5a and C5b-9 can act on immune cells and inflammatory states, and thus C5 cleavage inhibition can be a promising therapeutic target. In the pivotal pilot study for NMOSD, reported in Pittock et al., 14 patients with refractory NMOSD received ECU for 12 months. 69 The treatment regimen consisted of 600 mg i.v. ECU weekly for 4 weeks followed by 900 mg every 2 weeks starting on the fifth week for 48 weeks. After 12 months of ECU treatment, 12 of 14 patients were relapse-free. EDSS improved from 4.3 to 3.5 during the treatment period. A phase III randomized controlled trial is currently in progress (NCT01892345). Bacterial infections are common adverse effects. Severe meningococcal infections including meningococcal sepsis or meningoencephalitis have been reported. It is recommended that meningococcal vaccine should be given to patients planning ECU treatment.
Repositioning of immunotherapies
Several immunotherapies approved for other autoimmune diseases were shown to be effective for NMOSD as empirical therapies. They are being developed for repositioning as emerging therapies for NMOSD. Regular PLEX or plasmapheresis (IAPP and DFPP) has been described as effective in the prevention of the acute attacks. 70 Two patients, who were refractory to combination therapy of oral corticosteroid and immunosuppressants, showed a reduced relapse rate during regular PLEX or DFPP. It is suggested that the mechanism of action obliterates pathogenic AQP4-Ab, regulates complement system and inflammatory cytokines, and, thus, induces stability in the immune system.
The IVIg, considered as a candidate therapy for acute NMOSD attacks, might also be beneficial as a prevention therapy. Two case reports reported that patients unresponsive to oral corticosteroid and immunosuppressants, who received monthly/bimonthly IVIg, remained relapse-free for 1-5 years. 71, 72 Furthermore, another case series reported that the relapse rate decreased from 1.8 in the year before the treatment to 0.006 during bimonthly IVIg treatment, while seven of eight patients were relapse-free during the treatment. EDSS also improved from 3.3 to 2.6. 73 IVIg might be appropriate for children and pregnant patients, particularly when considering the contraindication of other immunosuppressants, corticosteroids and biologics.
Hematopoietic stem cell transplantation might be a promising option for the prevention of acute attacks in NMOSD, in addition to MS. Immunoablative therapies with high-dose immunosuppressants can lead to complete eradication and reset of the abnormal immune system, after the restoration of normal immune system function by stem cell transplantation. A few clinical trials are currently underway (NCT00787722).
Preclinical development
Preclinical animal models showed that several agents would be good candidate drugs for the prevention of NMOSD.
Pathogenic AQP4-Ab antibody blockade therapy AQP4-Ab is believed to be a pathogenic autoantibody in NMOSD. Blocking AQP4-Ab binding to AQP4 expressed on astrocytes can mitigate astrocytic damage through complement-mediated and cell-mediated cytotoxicity. A recently engineered non-pathogenic anti-AQP4 monoclonal antibody, aquaporumab, was reported to reduce NMO lesions in mouse models. 74 Furthermore, the chemical library screening technology showed that three drug-like small molecules, arbidol, tamarixetin and berbamine, and a synthetic peptoid ligand bind to AQP4-Ab. [75] [76] [77] Several bacterial cleavage enzymes target IgG antibodies. For example, endoglycosidase S (EndoS) 78 and IgG-degrading enzyme (IdeS) 79 target AQP4-Ab, and induce inactivation of pathogenic AQP4-Ab by disrupting CDC and antibody-dependent cell-mediated cytotoxicity.
Upregulation of complement inhibitor CD59
CD59 is a glycophosphoinositol-anchored membrane protein expressed on astrocytes, which inhibits the terminal membrane attack complex C5b-9. 80 In CD59 knockout mice, longitudinally extensive spinal cord lesions developed with increased CDC. 81 These results suggest that the upregulation of complement inhibitor CD59 is a potential NMOSD preventive treatment.
Class Kv1.3 channel inhibitor: Dalazatide
Blockade of voltage-dependent potassium channel Kv1.3 in effector memory T cells can suppress calcium signaling and inflammatory immune responses, including cytokine production and cell proliferation, which are deeply associated with the pathogenesis of autoimmune diseases. 82, 83 Dalazatide is a potent antagonist of the Kv1.3 channel and acts by blocking activation of autoreactive effector memory T cells, including T helper 1 and T helper 17, and reducing inflammatory cytokines. In animal models of MS and arthritis, dalazatide improved clinical scores, suggesting that, in addition to MS, it might hold a therapeutic promise for NMOSD. 82, 84 Conclusions A large number of basic and clinical studies have uncovered the pathogenicity of NMOSD. Immunosuppressive agents, corticosteroids, and plasma exchange/plasmapheresis with off-target immunosuppression and toxicity are still the mainstay of treatment for both acute attacks and prevention in NMOSD. In addition, therapeutic agents targeting specific molecules associated with the immunopathogenesis of NMOSD are currently being developed. To prevent acute inflammatory responses in the CNS, molecular-targeted agents based on inhibition of granulocytes, complement activation and increased humoral factors, such as VEGF, are anticipated as an add-on therapy to standard immunotherapies. Furthermore, several randomized clinical trials using monoclonal antibody targeting B cells, inflammatory cytokines and the classical complement pathway are currently underway for the prevention of acute attacks in NMOSD. Furthermore, preclinical therapeutic agents that target AQP4, pathogenic AQP4-Ab, complement inhibitors and T helper 17 cells will possibly proceed to clinical trials. A future goal is to shift from conventional treatments to highly selective therapies bearing fewer side-effects or combined therapies with off-target and molecular-target agents. 
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